1 January 2025 in Radiology
A cardiac MRI model incorporating the ischemic late gadolinium enhancement (LGE) parameters of extent, transmurality, location, and midwall LGE significantly outperformed traditional risk factors in predicting all-cause mortality in participants with ischemic cardiomyopathy.
1 April 2020 in Archives of Cardiovascular Diseases
1 October 2025 in Circulation: Cardiovascular Imaging
BACKGROUND: Stress perfusion cardiovascular magnetic resonance (CMR) is widely used to detect myocardial ischemia, mostly through visual assessment. Recent studies suggest that strain imaging at rest and during stress can also help in prognostic stratification. However, the additional prognostic value of combining both rest and stress strain imaging has not been fully established. This study examined the incremental benefit of combining these strain measures with traditional risk prognosticators and CMR findings to predict major adverse clinical events (MACE) in a cohort of consecutive patients referred for stress CMR. METHODS: This retrospective, single-center observational study included all consecutive patients with known or suspected coronary artery disease referred for stress CMR between 2016 and 2018. Fully automated machine learning was used to obtain global longitudinal strain at rest (rest-GLS) and global circumferential strain at stress (stress-GCS). The primary outcome was MACE, including cardiovascular death or hospitalization for heart failure. Cox models were used to assess the incremental prognostic value of combining these strain features with traditional prognosticators. RESULTS: Of 2778 patients (age 65±12 years, 68% men), 96% had feasible, fully automated rest-GLS and stress-GCS measurements. After a median follow-up of 5.2 (4.8–5.5) years, 316 (11.1%) patients experienced MACE. After adjustment for traditional prognosticators, both rest-GLS (hazard ratio, 1.09 [95% CI, 1.05–1.13]; P <0.001) and stress-GCS (hazard ratio, 1.08 [95% CI, 1.03–1.12]; P –10% for rest-GLS and stress-GCS, with a C-index improvement of 0.02, continuous net reclassification improvement of 15.6%, and integrative discrimination index of 2.2% (all P –10% provided an incremental prognostic value over and above traditional prognosticators, including CMR parameters, for predicting MACE in patients undergoing stress CMR.
12 September 2023 in Archives of Cardiovascular Diseases
1 August 2025 in Radiology
Artificial intelligence–based automated global longitudinal strain measured in 2830 consecutive patients who underwent stress cardiac MRI was independently associated with the occurrence of major adverse cardiovascular events.
30 July 2025 in JACC: Case Reports
A subcutaneous implantable cardioverter defibrillator (S-ICD) is a validated alternative to a transvenous ICD for patients without pacing indications. However, limited data exist regarding its safety and efficacy in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). A 21-year-old man was referred after a syncope during a sport event. A 12-lead electrocardiogram showed repolarization abnormalities, and cardiac magnetic resonance demonstrated right ventricular dilatation, biventricular dysfunction, and fibrosis compatible with a diagnosis of ARVC. An S-ICD was implanted after successful preimplant screening. Genetic testing identified a known pathogenic plakophilin-2 variant. The patient received an S-ICD. At 18 months, lead noise, undersensing, and oversensing occurred because of reduced QRS amplitude. Imaging confirmed disease progression. The S-ICD was explanted and replaced by a transvenous ICD. The patient was referred for heart transplant evaluation. Our case represents a phenotype variant of ARVC with failure of the S-ICD system due to a temporal change in QRS amplitude over a short period of time. Advanced discrimination algorithms on the S-ICD may not be sufficient to prevent device failure. Cardiac magnetic resonance and genetic testing could eventually play a major role in the selection of a device in patients with ARVC. This case illustrates S-ICD failure associated with rapidly progressive ARVC, underscoring the need for close follow-up and tailored device selection in this population.